Last reviewed · How we verify

rFVIIIFc — Competitive Intelligence Brief

rFVIIIFc (rFVIIIFc) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant clotting factor (Factor VIII replacement therapy). Area: Hematology.

marketed Recombinant clotting factor (Factor VIII replacement therapy) Factor VIII / FcRn (neonatal Fc receptor) Hematology Small molecule Live · refreshed every 30 min

Target snapshot

rFVIIIFc (rFVIIIFc) — Bioverativ Therapeutics Inc.. rFVIIIFc is a recombinant Factor VIII fused to the Fc domain of human immunoglobulin G, which replaces deficient clotting Factor VIII to restore hemostasis in hemophilia A patients.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
rFVIIIFc TARGET rFVIIIFc Bioverativ Therapeutics Inc. marketed Recombinant clotting factor (Factor VIII replacement therapy) Factor VIII / FcRn (neonatal Fc receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant clotting factor (Factor VIII replacement therapy) class)

  1. Bioverativ Therapeutics Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rFVIIIFc — Competitive Intelligence Brief. https://druglandscape.com/ci/rfviiifc. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: